Now showing items 1-3 of 3
Current and Future Therapeutic Targets for Pulmonary Arterial Hypertension
(Mary Ann Liebert, 2013-06)
Pulmonary arterial hypertension (PAH) remains a poorly understood disorder with dire consequences. Progression of disease often leads to right heart failure and death without lung transplantation. Limited therapeutic ...
Reduced expression of angiotensin I-converting enzyme in Caveolin-1 knockout mouse lungs
Reduced lung capillary expression of angiotensin I-converting enzyme (ACE), a key enzyme in cardiovascular pathophysiology, and of caveolin-1, an important regulator of endothelial cell signalling, has been demonstrated ...
Enhanced Ca2+-sensing receptor function in pulmonary hypertension
(Pharmaceutical Society of Japan, 2013)
Pulmonary arterial hypertension (PAH) is a rare, progressive, and fetal disease. The five-year survival rate after diagnosis is ～50%. In Japan, PAH is listed in the Specified Rare and Intractable Diseases. Pulmonary vascular ...